{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-007586","form_type":"8-K","ticker":"ARQT","cik":"0001787306","company_name":"Arcutis Biotherapeutics, Inc.","filed_at":"2024-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.535031+00:00","generated_at":"2026-06-05T09:13:52.690830+00:00","sec_items":["1.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Arcutis licenses ZORYVE to Sato for Japan; $25M upfront, up to $65M milestones","bullets":["Upfront payment of $25M; up to $10M in regulatory milestones and $30M in sales milestones.","Royalties of low double-digit to mid-teen double-digit percentage on net sales in Japan.","Sato exclusively develops and commercializes ZORYVE cream and foam for dermatological indications in Japan.","Arcutis retains approval and oversight rights over development and commercialization activities."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-007586","json":"https://secwatch.observer/filing/0001628280-24-007586.json","markdown":"https://secwatch.observer/filing/0001628280-24-007586.md","text":"https://secwatch.observer/filing/0001628280-24-007586.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787306/000162828024007586/0001628280-24-007586-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787306/000162828024007586/arqt-20240227.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T09:13:52.690830+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bcb882bac5cab60b4bb23c95e1dc2496d4c00dae","claim":"Arcutis Biotherapeutics, Inc. entered into License Agreement with Sato Pharmaceutical Co., Ltd. valued at an upfront payment of $25 million (effective 2024-02-27).","evidence_excerpt":"On February 27, 2024, Arcutis Biotherapeutics, Inc. (“Arcutis” or the “Company”) entered into a License Agreement (the “License Agreement”) with Sato Pharmaceutical Co., Ltd. (“Sato”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1787306/000162828024007586/0001628280-24-007586-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Sato Pharmaceutical Co., Ltd."},{"label":"Value","value":"an upfront payment of $25 million"},{"label":"Effective","value":"2024-02-27"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}